139 related articles for article (PubMed ID: 25982227)
1. Improvement of the immune efficacy of carbohydrate vaccines by chemical modification on the GM3 antigen.
Zheng XJ; Yang F; Zheng M; Huo CX; Zhang Y; Ye XS
Org Biomol Chem; 2015 Jun; 13(22):6399-406. PubMed ID: 25982227
[TBL] [Abstract][Full Text] [Related]
2. Cancer vaccines: an update with special focus on ganglioside antigens.
Bitton RJ; Guthmann MD; Gabri MR; Carnero AJ; Alonso DF; Fainboim L; Gomez DE
Oncol Rep; 2002; 9(2):267-76. PubMed ID: 11836591
[TBL] [Abstract][Full Text] [Related]
3. Stable GM3 lactone mimetic raises antibodies specific for the antigens expressed on melanoma cells.
Arcangeli A; Toma L; Contiero L; Crociani O; Legnani L; Lunghi C; Nesti E; Moneti G; Richichi B; Nativi C
Bioconjug Chem; 2010 Aug; 21(8):1432-8. PubMed ID: 20669938
[TBL] [Abstract][Full Text] [Related]
4. Engineering the binding site of an antibody against N-glycolyl GM3: from functional mapping to novel anti-ganglioside specificities.
Rojas G; Pupo A; Gómez S; Krengel U; Moreno E
ACS Chem Biol; 2013 Feb; 8(2):376-86. PubMed ID: 23138862
[TBL] [Abstract][Full Text] [Related]
5. Efficient metabolic engineering of GM3 on tumor cells by N-phenylacetyl-D-mannosamine.
Chefalo P; Pan Y; Nagy N; Guo Z; Harding CV
Biochemistry; 2006 Mar; 45(11):3733-9. PubMed ID: 16533056
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, conformational studies, binding assessment and liposome insertion of a thioether-bridged mimetic of the antigen GM3 ganglioside lactone.
Toma L; Di Cola E; Ienco A; Legnani L; Lunghi C; Moneti G; Richichi B; Ristori S; Dell'Atti D; Nativi C
Chembiochem; 2007 Sep; 8(14):1646-9. PubMed ID: 17705308
[No Abstract] [Full Text] [Related]
7. GM3(Neu5Gc) ganglioside: an evolution fixed neoantigen for cancer immunotherapy.
Labrada M; Dorvignit D; Hevia G; Rodríguez-Zhurbenko N; Hernández AM; Vázquez AM; Fernández LE
Semin Oncol; 2018 Jan; 45(1-2):41-51. PubMed ID: 30318083
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and immunological properties of N-modified GM3 antigens as therapeutic cancer vaccines.
Pan Y; Chefalo P; Nagy N; Harding C; Guo Z
J Med Chem; 2005 Feb; 48(3):875-83. PubMed ID: 15689172
[TBL] [Abstract][Full Text] [Related]
9. Key role of a structural water molecule for the specificity of 14F7-An antitumor antibody targeting the NeuGc GM3 ganglioside.
Bjerregaard-Andersen K; Abraha F; Johannesen H; Oscarson S; Moreno E; Krengel U
Glycobiology; 2021 Dec; 31(11):1500-1509. PubMed ID: 34735569
[TBL] [Abstract][Full Text] [Related]
10. Ganglioside GM3-based anticancer vaccines: Reviewing the mechanism and current strategies.
Zhang J; Terreni M; Liu F; Sollogoub M; Zhang Y
Biomed Pharmacother; 2024 Jul; 176():116824. PubMed ID: 38820973
[TBL] [Abstract][Full Text] [Related]
11. Chemical biology approaches to designing defined carbohydrate vaccines.
Anish C; Schumann B; Pereira CL; Seeberger PH
Chem Biol; 2014 Jan; 21(1):38-50. PubMed ID: 24439205
[TBL] [Abstract][Full Text] [Related]
12. Density-dependent recognition of cell surface GM3 by a certain anti-melanoma antibody, and GM3 lactone as a possible immunogen: requirements for tumor-associated antigen and immunogen.
Nores GA; Dohi T; Taniguchi M; Hakomori S
J Immunol; 1987 Nov; 139(9):3171-6. PubMed ID: 3668254
[TBL] [Abstract][Full Text] [Related]
13. Anti-GM3-lactam monoclonal antibodies of the IgG type recognize natural GM3-ganglioside lactone but not GM3-ganglioside.
Ding K; Rosén A; Ray AK; Magnusson G
Glycoconj J; 1992 Dec; 9(6):303-6. PubMed ID: 1305422
[TBL] [Abstract][Full Text] [Related]
14. Combining synthetic carbohydrate vaccines with cancer cell glycoengineering for effective cancer immunotherapy.
Qiu L; Gong X; Wang Q; Li J; Hu H; Wu Q; Zhang J; Guo Z
Cancer Immunol Immunother; 2012 Nov; 61(11):2045-54. PubMed ID: 22539085
[TBL] [Abstract][Full Text] [Related]
15. Cellular and humoral immune response to N-Glycolyl-GM3 elicited by prolonged immunotherapy with an anti-idiotypic vaccine in high-risk and metastatic breast cancer patients.
Guthmann MD; Castro MA; Cinat G; Venier C; Koliren L; Bitton RJ; Vázquez AM; Fainboim L
J Immunother; 2006; 29(2):215-23. PubMed ID: 16531822
[TBL] [Abstract][Full Text] [Related]
16. Crystal structure of an anti-ganglioside antibody, and modelling of the functional mimicry of its NeuGc-GM3 antigen by an anti-idiotypic antibody.
Talavera A; Eriksson A; Okvist M; López-Requena A; Fernández-Marrero Y; Pérez R; Moreno E; Krengel U
Mol Immunol; 2009 Oct; 46(16):3466-75. PubMed ID: 19748674
[TBL] [Abstract][Full Text] [Related]
17. Chemoenzymatic synthesis and biological evaluation of ganglioside GM3 and lyso-GM3 as potential agents for cancer therapy.
Li T; Wang X; Dong P; Yu P; Zhang Y; Meng X
Carbohydr Res; 2021 Nov; 509():108431. PubMed ID: 34492428
[TBL] [Abstract][Full Text] [Related]
18. Novel modification of ceramide: rat glioma ganglioside GM3 having 3-O-acetylated sphingenine.
Suetake K; Tsuchihashi K; Inaba K; Chiba M; Ibayashi Y; Hashi K; Gasa S
FEBS Lett; 1995 Mar; 361(2-3):201-5. PubMed ID: 7698323
[TBL] [Abstract][Full Text] [Related]
19. Synthesis of a GM3 ganglioside analogue carrying a phytoceramide moiety by intramolecular glycosylation as a key step.
Fujikawa K; Imamura A; Ishida H; Kiso M
Carbohydr Res; 2008 Nov; 343(16):2729-34. PubMed ID: 18571149
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and Evaluation of Liposomal Anti-GM3 Cancer Vaccine Candidates Covalently and Noncovalently Adjuvanted by αGalCer.
Yin XG; Lu J; Wang J; Zhang RY; Wang XF; Liao CM; Liu XP; Liu Z; Guo J
J Med Chem; 2021 Feb; 64(4):1951-1965. PubMed ID: 33539088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
